MINNEAPOLIS–(BUSINESS WIRE)–DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical firm targeted on growing novel remedies for extreme ischemic illnesses, introduced right this moment that the Firm’s administration will attend the fifteenth Annual Craig-Hallum Alpha Choose Convention on Tuesday, November 19, 2024 in New York Metropolis, New York. Administration shall be out there for one-on-one conferences all through the day.
Traders and attendees that wish to schedule a gathering with DiaMedica’s administration can contact their Craig-Hallum consultant to rearrange a gathering.
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. is a medical stage biopharmaceutical firm dedicated to enhancing the lives of individuals affected by critical ischemic illnesses with a give attention to acute ischemic stroke and preeclampsia. DiaMedica’s lead candidate DM199 is the primary pharmaceutically lively recombinant (artificial) type of the KLK1 protein, a longtime therapeutic modality in Asia for the therapy of acute ischemic stroke, preeclampsia and different vascular illnesses. For extra data go to the Firm’s web site at www.diamedica.com.
View supply model on businesswire.com: https://www.businesswire.com/information/residence/20241112148074/en/
Scott Kellen
Chief Monetary Officer
Cellphone: (763) 496-5118
skellen@diamedica.com
For Investor Inquiries:
Mike Moyer
Managing Director, LifeSci Advisors, LLC
mmoyer@lifesciadvisors.com
Supply: DiaMedica Therapeutics Inc.
